ISCT, International Society for Cell & Gene Therapy

ISCT is a global association driving the translation of scientific research to deliver innovative cellular therapies to patients.

Nextleaf Solutions (CSE:OILS) (OTCQB:OILFF)

Nextleaf is a federally regulated producer of cannabis oil that owns one of the largest portfolios of U.S. patents for the extraction and distillation of cannabinoids. Nextleaf distributes cannabis vapes and distilled oils in Canada under its award-winning prohibition-era brand, Glacial Gold™, and supplies cannabis ingredients to its wholesale customers. Nextleaf’s patented closed-loop automated extraction plant in Metro Vancouver efficiently transforms cannabis and hemp grown in B.C. and throughout Canada into high-purity cannabis distillate at an industrial scale. Nextleaf is developing delivery technology and differentiated cannabinoid-based formulations through its Health Canada Research Licence with sensory evaluation of cannabis via human testing. The Company owns 17 U.S. patents and has been issued 90 patents globally. Nextleaf Solutions trades as OILS on the Canadian Securities Exchange, OILFF on the OTCQB Market in the United States

Lux Bio

Lux Bio is the first company in the world developing enzyme-powered light for real-world applications. Our long-duration enzyme platform unlocks multi-billion-dollar markets across safety, defense, entertainment, cosmetics, therapeutics, and more. We’re proudly backed by the Canadian Coast Guard, NASA, and top-tier partners across biotech and climate innovation. To date, Lux Bio has raised over $4.5M in pre-seed funding, including both venture capital and non-dilutive grants. Venture capital firms backing Lux Bio include: 🟢 SOSV / IndieBio (world’s leading biotech accelerator) 🟢 Climate Capital (climate tech pioneers) 🟢 AgFunder (top ag/biotech VC) 🟢 Brickyard VC (high-conviction early-stage firm) Non-dilutive funding and institutional support provided by: 🟢 Creative Destruction Labs – Oceans and Space 🟢 Natural Products Canada 🟢 National Research Council of Canada 🟢 Sustainable Development Technology Canada (SDTC) 🟢 Innovative Solutions Canada Our flagship product, Lume, is a marine-safe glow stick alternative built for defense and SAR operations. We have inbound orders coming in from around the world—and that's just the beginning. We’re actively seeking strategic partners and investors to help us scale production and meet global demand. If you’re looking to back a category-defining company building the future of sustainable light—let’s talk. 📩 [email protected]

SignalChem Biotech Inc.

SignalChem is now a part of Sino Biological. SignalChem is a biotechnology company focused on the research, development and production of innovative cell signaling products for the advancement of basic life sciences research and drug discovery efforts. Specific emphasis is placed on the production of highly purified biologically-active human recombinant proteins. SignalChem is a leader in the recombinant protein market. We strive to produce products to fulfill the needs of scientists in both academia and the biotech industry. All of SignalChem’s products are subjected to rigorous testing and quality control analyses to ensure the highest quality proteins are produced.

VoxCell BioInnovation

VoxCell BioInnovation is advancing the future of in vitro modeling. We develop 3D bioprinted, vascularized human-like tissue models that closely replicate native biology, offering a powerful tool for more predictive, physiologically relevant research. Leveraging our proprietary high-resolution bioprinter, advanced vascularization software, and Universal Bioinks™, we produce complex tissue models that mirror patient biopsy samples in structure and function. Our flagship product is a 3D vascularized model of Triple Negative Breast Cancer (TNBC), designed to support applications in disease modeling, drug screening, vascular toxicity, and targeted delivery. Delivered as ready-to-use, perfusable models, VoxCell’s consumable products serve pharmaceutical companies, biotech firms, CROs, and academic researchers seeking to reduce translational gaps and accelerate biomedical innovation.